There are currently 24 clinical trials in Murrieta, California looking for participants to engage in research studies. Trials are conducted at various facilities, including United Medical Doctors and Tri-Valley Urology Medical Group. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Recruiting
The goal of this study is to learn if GS-1427 is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo (Part 1), and participants treated with GS-1427 or ustekinumab alone with participants treated with GS-1427 in combination with ustekinumab (Part 2). The primary objectives of this study are: Part 1: To assess the efficacy of GS-1427,... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/20/2024
Locations: United Medical Doctors, Murrieta, California
Conditions: Ulcerative Colitis
Register for Updates
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
NCT05831176
Recruiting
The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the eff... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/20/2024
Locations: United Medical Doctors, Murrieta, California
Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis, Eosinophilic Gastrointestinal Disease
Register for Updates
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06101095
Recruiting
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) Screening period: Up to 12 weeks before Week 0 Randomized double-blind period: 24 weeks Open l... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: United Clinical Research Site Number : 8400001, Murrieta, California
Conditions: Eosinophilic Oesophagitis
Register for Updates
Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy
NCT05575401
Recruiting
The goal of this treatment study is to determine if doing lateral pharyngoplasty with tonsillectomy is better for children than doing tonsillectomy alone. The main questions it aims to answer are: Do children experience less pain after surgery when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone? Do children eat/drink better when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone? Is there a lower risk of bleeding after... Read More
Gender:
All
Ages:
Between 3 years and 17 years
Trial Updated:
06/17/2024
Locations: Loma Linda University Professional Building - Murrieta, Murrieta, California
Conditions: Sleep-Disordered Breathing, Sleep Apnea Syndromes in Children, Sleep Apnea, Obstructive, Tonsillitis, Tonsillar Hypertrophy, Tonsil Stone, Tonsil Disease
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Ferring Investigational Site, Murrieta, California
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
NCT04173273
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/07/2024
Locations: Temecula Valley Imaging [CXR Only], Murrieta, California +5 locations
Conditions: Crohn's Disease
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/06/2024
Locations: United Medical Doctors, Murrieta, California
Conditions: Crohn's Disease
Register for Updates
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
05/31/2024
Locations: United Surgery Center Murrieta [Endoscopy Only], Murrieta, California +1 locations
Conditions: Ulcerative Colitis
Register for Updates
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
NCT06285214
Recruiting
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Tri Valley Urology Medical Group, Murrieta, California
Conditions: Interstitial Cystitis/Bladder Pain Syndrome
Register for Updates
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
NCT05740007
Recruiting
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/30/2024
Locations: Tri Valley Urology Medical Group, Murrieta, California
Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: United Medical Doctors, Murrieta, California
Conditions: Ulcerative Colitis
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2024
Locations: United Medical Doctors, Murrieta, California
Conditions: Ulcerative Colitis
Register for Updates